纤溶酶原激活剂在卒中治疗中的作用:纤溶及其超越
尽管血栓切除术的技术进步革新了急性卒中治疗,卒中相关残疾和死亡发生率仍高,纤溶酶原激活剂(真核、细菌或工程化形式)仍常用于缺血性卒中的急性治疗,并成为临床研究的关键领域。然而试验中不一致的结果、疗效证据不足或副作用报告可能减少其临床使用;其作用机制可能超出血管腔并涉及非纤溶酶原依赖过程,提示非纤溶作用。
要点
- 纤溶酶原激活剂通过将纤溶酶原转化为活性纤溶酶促进纤维蛋白溶解和血凝块分解。
- 纤溶酶原激活剂在缺血性卒中中可再通闭塞动脉,在出血性卒中中可加速血肿清除。
- 试验中不一致结果、疗效证据不足或副作用报告可能减少纤溶酶原激活剂的临床使用。
核心结论
- 纤溶酶原激活剂仍常用于缺血性卒中的急性治疗,并成为临床研究的关键领域。
- 理解纤溶酶原激活剂的复杂作用机制可指导卒中患者未来治疗干预的方向。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 纤溶酶原激活剂包括真核、细菌或工程化形式,可促进纤维蛋白溶解。
- 纤溶酶原激活剂在缺血性卒中中可再通闭塞动脉,在出血性卒中中可加速血肿清除。
- 试验中不一致结果、疗效证据不足或副作用报告可能减少纤溶酶原激活剂的临床使用。
- 纤溶酶原激活剂的作用机制可能超出血管腔并涉及非纤溶酶原依赖过程,提示非纤溶作用。
局限性
- 试验中不一致结果、疗效证据不足或副作用报告可能减少纤溶酶原激活剂的临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although recent technical advances in thrombectomy have revolutionised acute stroke treatment, prevalence of disability and death related to stroke remain high. Therefore, plasminogen activators-eukaryotic, bacterial, or engineered forms that can promote fibrinolysis by converting plasminogen into active plasmin and facilitate clot breakdown-are still commonly used in the acute treatment of ischaemic stroke. Hence, plasminogen activators have become a crucial area for clinical investigation for their ability to recanalise occluded arteries in ischaemic stroke and to accelerate haematoma clearance in haemorrhagic stroke. However, inconsistent results, insufficient evidence of efficacy, or reports of side-effects in trial settings might reduce the use of plasminogen activators in clinical practice. Additionally, the mechanism of action for plasminogen activators could extend beyond the vessel lumen and involve plasminogen-independent processes, which would suggest that plasminogen activators have also non-fibrinolytic roles. Understanding the complex mechanisms of action of plasminogen activators can guide future directions for therapeutic interventions in patients with stroke.
引用
- Thiebaut AM, Gauberti M, Ali C, et al. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond. Lancet Neurol. 2018. PMID: 30507392. doi:10.1016/S1474-4422(18)30323-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。